Vaginal Atrophy (VA) is a chronic and progressive condition. VA impacts on the quality of life, relationships, everyday activities and confidence of women sufferers. It is associated with thinning, drying and inflammation of the v...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
VACS-D
Vaginal Arco ColpoSuspension Device for the treatment of Uri...
976K€
Cerrado
RTC-2017-6524-1
Desarrollo de un nuevo tratamiento farmacológico para la seq...
301K€
Cerrado
JDC2023-051081-I
Tratamiento de la obesidad sarcopénica en mujeres postmenopá...
72K€
Cerrado
identifyHer
A DIRECT 2 CONSUMER SOLUTION FOR PERIMENOPAUSAL SYMPTOM DETE...
75K€
Cerrado
Duración del proyecto: 31 meses
Fecha Inicio: 2022-05-12
Fecha Fin: 2024-12-31
Líder del proyecto
AVETA MEDICAL LIMITED
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
4M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Vaginal Atrophy (VA) is a chronic and progressive condition. VA impacts on the quality of life, relationships, everyday activities and confidence of women sufferers. It is associated with thinning, drying and inflammation of the vaginal tissue. It is experienced by 80% of all women globally and is the most common symptom of the menopause. Over 70% of Breast Cancer Survivors will also suffer from VA due to side effects of chemotherapy and the cancer-blocker drugs they take further exacerbate symptoms of VA. Current treatment options for VA, primarily pharmaceuticals are either ineffective or poorly tolerated. In the EU and US, 3.6m patients of VA reject existing treatments.
AVeta- a medical device delivering the only hormone free, affordable and safe targeted therapy for all women suffering from VA. Solution is based on pathophysiology of wound healing and will be prescribed by a Clinician in an outpatient setting and women will self-administer the therapy monthly at home.